CVGR Covalent

WAYNE, Penn., Nov. 7 /PRNewswire-FirstCall/ -- Covalent Group, Inc. (NASDAQ:CVGR) today announced that it will release financial results for the 2005 third quarter on Thursday, November 10, 2005, after market close with an accompanying conference call on Friday, November 11 at 9:00 A.M. ET. To participate in the live call by telephone, please dial (877) 407-4018 from the U.S., or for international callers, please dial (201) 689-8471. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's Web site at http://www.covalentgroup.com/. Please go to the Web site 15 minutes prior to the scheduled start to register, download, and install any necessary audio software. A webcast audio replay will be available on the Company Web site for 31 days through Monday, December 11, 2006. A telephone audio replay will also be available for 10 days through Monday, November 21, 2005, by dialing (877) 660-6853 from the U.S., or (201) 612-7415 for international callers, and entering account number 3055 and conference ID number 174310 when prompted. About Covalent Group Covalent Group is a clinical research organization that is a leader in the design and management of complex clinical trials for the pharmaceutical, biotechnology and medical device industries. The Company's mission is to provide its clients with high quality, full-service support for their clinical trials. Covalent offers therapeutic expertise, experienced team management and advanced technologies. The Company has clinical trial experience across a wide variety of therapeutic areas such as cardiovascular, endocrinology/metabolism, diabetes, vaccines, biologics, gene therapy, immunology, neurology, oncology, infectious diseases, gastroenterology, dermatology, hepatology, women's health and respiratory medicine. Covalent believes that its leadership in the design of complex clinical trials, its application of innovative technologies, therapeutic expertise and commitment to quality offer its clients a means to more quickly and cost effectively develop products through the clinical trial process. With its wholly-owned international subsidiary, Covalent Group, Ltd., as well as its Strategic Partners operating in various regions around the world, Covalent is able to meet the global drug development needs of its clients. Investor Relations Contact: Lawrence Hoffman, CPA, Esq. CFO, Covalent Group, Inc. (610) 975-9533 Contact us on-line: http://www.covalentgroup.com/ DATASOURCE: Covalent Group, Inc. CONTACT: Lawrence Hoffman, CPA, Esq., CFO of Covalent Group, Inc., +1-610-975-9533 Web site: http://www.covalentgroup.com/

Copyright